| (Values in U.S. Thousands) | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 | Jun, 2020 |
| Sales | 4,381,000 | 4,263,000 | 4,828,000 | 3,998,000 | 3,094,300 |
| Sales Growth | +2.77% | -11.70% | +20.76% | +29.21% | +22.89% |
| Net Income | -1,043,000 | -256,000 | 519,000 | 585,000 | 220,700 |
| Net Income Growth | -307.42% | -149.33% | -11.28% | +165.07% | +60.63% |
Catalent Inc (CTLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs (protein, cell, and gene therapy biologics) and consumer health products.
Fiscal Year End Date: 06/30